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DIFFERENTIAL EFFECTS OF EPIDERMAL GROWTH FACTOR RECEPTOR 
INHIBITORS ON GLIOBLASTOMA MULTIFORME 
ILYSE N. BLAZAR 
ABSTRACT 
Objective: Glioblastoma Multiforme (GBM), one of the most malignant forms of primary 
brain tumors, is characterized by its highly heterogenous genetic composition, aggressive 
infiltration of surrounding tissue, and resistance to current treatments. Gene expression 
analysis has characterized GBM into four main types, with a significant portion 
belonging to the Classical subtype, typified by overexpression and/or mutation of the 
epidermal growth factor receptor (EGFR). Also common to this subtype of GBM is the 
loss of crucial tumor suppressor genes Ink4A/ARF and PTEN, which contribute to the 
invasive nature and unregulated proliferation that underlie the GBM pathology.  The high 
rate of tumor recurrence post treatment with surgical resection, chemotherapy, and 
radiation has driven the pursuit of more effective molecularly targeted therapies. This 
study was undertaken to determine the effects of two types of small molecule tyrosine 
kinase inhibitors on cells overexpressing wild-type EGFR in the context of their 
respective complements of tumor suppressor genes.   
Methods: Several cell lines were established from mouse models of EGFR wild-type 
(EGFRWT) driven gliomagenesis and treated with 10 µM of type I tyrosine kinase 
inhibitors Gefitinib (Iressa®, Astra Zeneca), CI-1033 (Canertinib, Pfizer), or Dimethyl 
Sulfoxide vehicle. Cells were exposed to each drug treatment as part of a time course 
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ranging from 0 to 24 hours and then evaluated by trypan blue exclusion and Western blot 
analysis for cell viability and molecular and biochemical effects respectively.  
Results: Evaluation of cell viability indicated that CI-1033 caused a greater increase in 
cell death than gefitinib when compared to control treated cells regardless of the tumor 
suppressors lost. Gefitinib was found to cause cell death only in cells expressing the 
PTEN tumor suppressor whereas CI-1033 showed similar levels of cell death for cells 
deficient in Ink4A/ARF or both Ink4A/ARF and PTEN tumor suppressors. Western blot 
analysis revealed that CI-1033 more effectively inhibited EGFR compared to gefitinib. 
Treatment with both gefitinib and CI-1033 effectively blocked phosphorylation of EGFR, 
but this effect was less pronounced with gefitinib treatment. Further analysis of 
downstream signaling molecules showed a greater presence of cleaved caspase 3, a 
hallmark of apoptosis, in gefitinib treated cells expressing PTEN than in those cells 
treated with CI-1033. Cells deficient in both Ink4A/ARF and PTEN did not demonstrate 
any induction of cleaved caspase 3 following either treatment.  
Conclusions: Based on the significant differences in cell viability between treatments, CI-
1033 is an overall more effective inhibitor of EGFRWT expressing cells lacking PTEN, 
while gefitinib and CI-1033 were found to be similarly effective in cells expressing 
PTEN. The results of western blot analysis indicate that total and irreversible EGFR 
inhibition may be necessary to induce cell death in a manner that effectively terminates 
downstream cell signaling. It is likely that CI-1033, unlike gefitinib, induces apoptosis in 
a caspase-independent manner, which may be one of the many differences in downstream 
effects produced by these two drugs. Further research is necessary to determine the extent 
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to which each inhibitor shuts down proliferative cell signaling pathways such as PI3K-
AKT and MEK-ERK signaling pathways downstream of EGFR. Overall, these data 
indicate that genotype plays an important role in the determination of therapeutic 
response and may aid in the evaluation of clinical prognoses.  
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INTRODUCTION 
 
 Glioblastoma Multiforme (GBM) is one of the deadliest and most common forms 
of central nervous system (CNS) cancer. Accounting for 40% of all primary tumors and 
80% of all high grade primary CNS neoplasms, patients with GBM are faced with a 
rapidly progressing disease, extremely poor prognoses, and a median survival of 12-14 
months (H. B. Newton, 1994). Difficulties with drug delivery across the blood- brain and 
blood- tumor barriers (BBB, BTB) and the extremely infiltrative character of GBM pose 
significant challenges in the pursuit of effective therapeutics (Herbert B. Newton, 2010) 
Zhu et al., 2009). Current treatments include surgical resection of tumors, chemotherapy, 
and radiation, but their inability to significantly prolong survival rates has driven research 
efforts toward more effective molecularly targeted therapies to combat these highly 
infiltrative tumors and transition patient care from palliative to curative (Hyun Jung Jun, 
Bronson, & Charest, 2014).  
 
Tumor Classification  
  
Gliomas are extremely heterogeneous and contain multiple subpopulations of 
cells that exhibit distinct gene expression profiles within a single tumor (Snuderl et al., 
2011). This mosaic gene expression plays a crucial role in the ability of these tumors to 
proliferate beyond mechanisms of cell cycle control and develop resistance to available 
therapies (Snuderl et al., 2011). For this reason, GBM is not only difficult to treat on a 
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universal scale, but also on an individual basis. The de novo emergence of GBM usually 
occurs in older patients (primary GBM), but can also be the result of the recurrence of a 
lower-grade astrocytic tumor in a younger patient (secondary GBM) (Welsh, 2010). The 
World Health Organization (WHO) classifies gliomas using a grading system consisting 
of grades I-IV, with grade I being the most benign form that can usually be surgically 
removed with almost no risk of recurrence. Grades II and III infiltrate the surrounding 
neural tissue with varying degrees of malignancy and can be further classified based on 
the cell type, astrocytes or oligodendrocytes, to which the glioma bears the closest 
resemblance. Grade IV tumors are the most aggressive form, referred to as GBM, and are 
often associated with severe necrosis, endothelial proliferation, and angiogenesis 
(Hambardzumyan, Parada, Holland, & Charest, 2011; Moore & Kim, 2010). Gliomas 
often exhibit enhanced cell motility, proliferation, and resistance to the initiation of 
apoptosis. These alterations in cell signaling allow tumors to reinvade areas as close as 2-
3 cm from former surgical resection cavities in 95% of cases, making total eradication 
nearly impossible (Giese, Bjerkvig, Berens, & Westphal, 2003).  
 In addition to the WHO grading system, tumors are also classified molecularly 
based on gene expression and tumor progression events and are referred to as either 
Mesenchymal, Proneural, Neural, or Classical (Verhaak et al., 2010). The Mesenchymal 
subtype is characterized by deletions or abnormalities in the Neurofibromatosis type 1 
(NF1) tumor suppressor gene and often expresses co-mutations of NF1 with the 
phosphatase and tensin homolog (PTEN) tumor suppressor (Verhaak et al., 2010). Genes 
in the tumor necrosis factor super family pathway are highly expressed and may be the 
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cause of the widespread necrosis and inflammatory infiltrates commonly observed in 
tumors of the Mesenchymal subtype (Verhaak et al., 2010). The Proneural subtype, one 
which shows the poorest response to aggressive therapy, typically harbors alterations in 
platelet derived growth factor receptor alpha type (PDGFRA) and point mutations in 
isocitrate dehydrogenase 1 (IDH1) genes (“Four Subtypes of Glioblastoma Discovered,” 
n.d.; Verhaak et al., 2010). In contrast, the Neural class is identified by the presence of 
neuron markers and does not exhibit a strong pattern in mutation or alteration of a 
particular gene(s) like the other subtypes (Verhaak et al., 2010). Neural tumors often 
share similarities with multiple other classes making them the most diverse category 
(Verhaak et al., 2010). The division of tumors into subtypes has enabled the emergence 
of survival patterns and differing degrees of delayed mortality based on the subtype as 
well as demonstrates the need for specifically targeted therapies for each group (Verhaak 
et al., 2010). 
Classical GBM, the tumor subtype modeled in the present study, includes 
amplification of chromosome 7 and deletion of chromosome 10 in 100% of cases 
(Verhaak et al., 2010). Gliomas belonging to the Classical subtype exhibit mutations 
allowing the amplification and/or constitutive activation of the epidermal growth factor 
receptor (EGFR), a receptor tyrosine kinase (RTK) that is overexpressed and mutated in 
over 50% of tumors (Hambardzumyan et al., 2011; Verhaak et al., 2010; Zhu et al., 
2009). Patients diagnosed with tumors belonging to the Classical subtype survive the 
longest in response to aggressive treatment, consisting of concurrent chemotherapy and 
radiation or more than four cycles of chemotherapy, in comparison to the other three 
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classes (“Four Subtypes of Glioblastoma Discovered,” n.d.; Verhaak et al., 2010). 
Classical tumors exhibiting mutations and/or overexpression of EGFR typically harbor 
mutations in cyclin-dependent kinase inhibitor 2A (CDKN2A), a locus coding for the 
Ink4A and ARF tumor suppressor genes, and loss of heterozygosity on chromosome 
10q23, which contains the PTEN tumor suppressor gene (Hambardzumyan et al., 2011; 
Krakstad & Chekenya, 2010). Loss of these key tumor suppressor genes is a crucial 
element in the development of fully penetrant Classical GBM (Zhu et al., 2009).  
EGFR expression is not only relevant to patients and scientists invested in the 
study of and cure for GBM, but also to many other scientific and medical communities 
due to its widespread involvement in a multitude of cancers outside of the CNS 
(Hambardzumyan et al., 2011). Mutation and atypical expression of EGFR with a diverse 
range of oncogenic characteristics serves as a common denominator among many cancers 
including colon, prostate, and breast (Hambardzumyan et al., 2011; Rixe et al., 2009; 
Skvortsov et al., 2005). The ability to decipher the associated downstream effectors and 
full consequences of receptor activity presents many opportunities for advancement and 
the next generation of effective molecularly targeted therapies.  
Growth Factor Signaling  
The epidermal growth factor receptor, EGFR, is a member of the ErbB1 family of 
RTKs that plays a critical role in normal physiological processes of growth and 
development, but when dysregulated and/or mutated contributes tremendously to tumor 
initiation and progression (Holbro, Civenni, & Hynes, 2003; Lemmon, Schlessinger, & 
Ferguson, 2014). Members of the ErbB1 receptor family share a common set of structural 
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features that include an extracellular ligand binding domain, one transmembrane domain, 
and a cytoplasmic protein kinase domain (Holbro et al., 2003). The extracellular domain 
is divided into four domains, with Domains I and III containing the primary ligand 
binding regions (Lemmon et al., 2014). Different ErbB family members contain divergent 
sets of tyrosine phosphorylation sites (Figure 1) in their carboxy-terminal tails giving 
each specific receptor the ability to produce a unique response to ligand activation with 
some overlap between related RTKs (Lemmon et al., 2014). EGFR regulates a variety of 
functions and knockout of the EGFR gene in mice has produced a wide range of 
outcomes that range from embryonic lethality to postnatal death with notable defects in 
the structure and function of bone, brain, and heart (Lemmon et al., 2014).  
 
 
Figure 1: EGFR & Phosphorylation Sites. Graphic representation of EGF 
binding EGFR showing intracellular phosphorylation sites and their associated signaling 
pathways. Taken from (“The Alain Charest Lab | Sackler,” n.d.).  
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EGFR ligands contain a domain that resembles epidermal growth factor (EGF) 
that allows them to bind specifically to the receptor (Holbro et al., 2003). Ligands are 
produced as membrane bound precursor proteins that are later cleaved by proteases to 
create active growth factors (Lemmon et al., 2014). Many ligands bind specifically to 
ErbB1 receptors, including EGF, amphiregulin (AR), and transforming growth factor 
alpha (TGF-α), while others have dual specificity such as those for ErbB1 and ErbB4 
receptors including betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin 
(EPR) (Holbro et al., 2003). Upon ligand binding, the four extracellular domains of 
EGFR dimerize, activating the receptor kinase domain. This activation allows for the 
autophosphorylation of specific tyrosine residues within the cytoplasmic domain that 
produce second messengers in several intracellular pathways including Mitogen 
Activated Protein Kinase (MAPK) and Phosphatidylinositol-3 kinase (PI3K) (Holbro et 
al., 2003). EGFR overexpression and/or uncontrolled activation have countless 
implications for affected cells and the surrounding tissue microenvironment because it is 
linked to such a diverse complement of downstream cell signaling pathways (Figure 2). 
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Figure 2: EGFR Signaling. EGF binding to EGFR activates a variety of downstream 
cell signaling pathways. Some of the widely studied pathways and their roles in cell 
function are pictured. Figure taken from (Kolch & Pitt, 2010).  
 
 The most common mechanism of EGFR overexpression in tumors is the 
amplification of wild-type EGFR (EGFRWT) and occurs in 40-50% of primary GBM 
(Herbert B. Newton, 2010). Many high grade gliomas also overexpress EGFR ligands 
such as EGF and TGF-α that create autocrine and paracrine stimulatory loops that further 
stimulate membranes with a high density of receptors (Herbert B. Newton, 2010). In 
addition to overexpression of EGFRWT, amplification of the EGFR gene leads to the rise 
of mutant forms, the most common being EGFR variant III (EGFRvIII) (Carrasco-
García, Saceda, & Martínez-Lacaci, 2014). Occurring in 20-30% of GBM, EGFRvIII 
mutations consist of a deletion in a region between exons 2 and 7 that causes the loss of 
the extracellular ligand binding domain and ligand independent constitutive activity of 
EGFR (Carrasco-García et al., 2014; Krakstad & Chekenya, 2010). The constitutive 
	  8 
action of EGFRvIII mutants and overexpression of EGFRWT both afford GBM tumor 
cells the ability to proliferate continuously, while circumventing contact inhibition and 
other cell cycle checkpoints that would ordinarily induce an apoptotic response (Holbro 
et al., 2003). Tumors that grow beyond a certain size require access to nutrients and 
oxygen through angiogenesis and may metastasize beyond the site of the primary tumor 
(Holbro et al., 2003).  
In addition to EGFR overexpression and amplification, concomitant loss of vital 
tumor suppressor genes contributes to the rapid onset of extremely penetrant gliomas. 
Both PTEN and Ink4A/ARF are vital regulators of growth and proliferation and play key 
roles in checkpoints for cell cycle arrest (Kim & Sharpless, 2006; Vitucci et al., 2013). 
Under normal physiological conditions, Ink4A functions as an inhibitor of cyclin-
dependent kinases, which promote cell growth via phosphorylation of the retinoblastoma 
family of proteins (Kim & Sharpless, 2006). The loss of Ink4A results in a weakened 
ability to impose cell cycle arrest and suppress abnormal growth (Kim & Sharpless, 
2006). The tumor suppressor function of ARF lies within its ability to regulate p53 in 
response to abnormal growth and/or damage by binding and inactivating the MDM2 
protein, which normally serves to negatively regulate p53 (Kim & Sharpless, 2006). 
PTEN serves as a tumor suppressor under normal conditions through the negative 
regulation of PI3K activity (Krakstad & Chekenya, 2010). The loss of PTEN allows 
enhanced PI3K signaling and is associated with an especially poor prognosis among 
GBM patients (Krakstad & Chekenya, 2010). 
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Mice with PTEN null genotypes are embryonically lethal and cells that 
experience loss and/or mutation of PTEN exhibit pathologies associated with the 
disruption of the G1/S cell cycle checkpoint (Vitucci et al., 2013). Similar inactivating 
PTEN mutations or deletions occur in 30-40% of human GBM (Vitucci et al., 2013). 
Loss of Ink4A/ARF and PTEN, when combined with overexpression of EGFRWT or 
EGFRvIII, leads to the manifestation of GBM in mouse models that bear close 
pathological and molecular resemblance to human GBM (Zhu et al., 2009). Increased 
receptor activity and signaling coupled with the loss of fundamental cell cycle control 
mechanisms are two critical factors that afford GBM such deadly pathological outcomes.  
Current Treatments 
The high frequency and diverse range of mutations that occur in GBM contribute 
to its ability to create diffuse tumors and to its overall resistance to current available 
therapies. A typical course of treatment begins with surgical resection in order to remove 
as much of the tumor as possible. Without damaging vital neurological structures, 
surgical resection may prolong patient survival and alleviate many symptoms 
(“Glioblastoma Cure Remains Elusive Despite Treatment Advances,” n.d.). Following 
surgery, patients usually begin a standard course of treatment that includes radiation and 
chemotherapy. Two United States Food and Drug Administration (FDA) approved 
chemotherapies are almost always included in the standard GBM treatment regimen. Oral 
temozolomide is given during radiation for newly diagnosed patients and bevacizumab 
(Avastin®), which received accelerated FDA approval, is given for the treatment of 
recurrent GBM (“Glioblastoma Cure Remains Elusive Despite Treatment Advances,” 
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n.d.; Lau, Magill, & Aghi, 2014). Temozolomide is a traditional alkylating agent that 
improves the median patient survival rate when compared to radiation alone, but overall 
has not proven to be effective against rapidly mutating GBM (Lau et al., 2014). 
Bevacizumab consists of a humanized monoclonal antibody that specifically binds 
Vascular Endothelial Growth Factor (VEGF), disrupting the tumor’s ability to induce 
angiogenesis (Lau et al., 2014). For patients with recurrent GBM, the treatment options 
are usually limited to chemotherapy alone because radiation can only be administered a 
second time if the cancer recurs in a different area of the brain due to toxicity concerns 
(“Glioblastoma Cure Remains Elusive Despite Treatment Advances,” n.d.). Although 
chemotherapy and radiation have proven to extend the five year overall survival rate to 
approximately 3%, neither has demonstrated to be curative by any means (“Glioblastoma 
Cure Remains Elusive Despite Treatment Advances,” n.d.). As tumors recur, treatment 
options are limited further and patient outcomes grow even bleaker. The lack of positive 
results produced from these conventional treatments has fueled research in the direction 
of molecularly targeted therapies that can specifically focus on the means of tumor 
growth and proliferation.  
Tyrosine Kinase Inhibitors 
As surgical resection, radiation, and current chemotherapy continue to produce 
extremely minimal survival among GBM patients, a novel class of drugs has been 
developed. These molecularly targeted therapies aim to specifically inhibit RTK activity 
in GBM cells by inhibiting EGFR, whose activity is crucial to cell survival and the 
maintenance of a hyper-proliferative state (Vivanco et al., 2012). The use of Tyrosine 
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Kinase Inhibitors (TKI) is undergoing investigation in a variety of experimental studies 
with an emphasis on two major classes of TKIs; Type I binds the active conformation of 
EGFR, while type II binds the inactive conformation (Vivanco et al., 2012).  
 Gefitinib (Iressa®, Astra Zeneca), a type I reversible TKI, has been successfully 
used to treat non-small cell lung cancer (NSCLC) tumors with activating EGFR 
mutations, but has proven largely unsuccessful in treating GBM (Park & Lemmon, 2012). 
Its reversible binding to the active conformation of the kinase domain is effective for 
NSCLC patients, but for reasons that are not well understood, does not seem to induce 
adequate inhibition to cause enough cell cycle arrest in GBM (Park & Lemmon, 2012). In 
a study conducted by Parker et al. 2013, gefitinib significantly reduced the migration of 
GBM tumor cells, making it a promising candidate as an anti invasive agent.   
 CI-1033 (Canertinib, Pfizer), a type I irreversible TKI, has been shown to increase 
expression of pro-apoptotic proteins and caspase-3 activation via EGFR in tumor cells 
derived from acute lymphoblastic leukemia as well as induce widespread cell death in 
EGFR addicted NSCLC (Irwin et al., 2013; Park & Lemmon, 2012). In a randomized 
phase II clinical trial treating metastatic breast cancer, its anti-tumor activity against 
EGFR driven tumors displayed promising results, but its toxicity levels at higher doses 
have not allowed it to progress to larger phase III clinical trials (Rixe et al., 2009).  
The Present Study 
Despite promising advances in molecularly targeted therapies, TKIs like gefitinib 
and CI-1033 have not been able to achieve success in the clinical treatment of GBM (Lau 
et al., 2014). This study aims to determine the levels of cell death induced by exposure to 
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these drugs and to ascertain the differences in their biochemical and molecular 
mechanisms as they pertain to cells overexpressing EGFRWT. An in-depth understanding 
of these mechanisms may pave the way for the advent of more effective therapies and/or 
the use of combination therapies with multiple targets. An appreciation of the 
mechanisms of action employed by these treatments may allow us to begin to piece 
together the facets of GBM that remain ambiguous.  
 In order to examine the effects of EGFR inhibition by gefitinib and CI-1033, 
mouse models were created to express genotypes similar to those found in EGFRWT 
GBM (Acquaviva et al., 2011; H. J. Jun et al., 2012; Zhu et al., 2009). At the onset, the 
mice were Ink4A/ARF-/- with a PTEN floxed allele conferring loss of PTEN upon cre 
expression. In order to create the specifically desired genotype, these mouse models 
contain a knocked in allele of human wild type EGFR in the collagen locus. Since 
EGFRWT is preceded by a stop cassette floxed with loxP sites, EGFRWT is only expressed 
following cre infection. Using cre delivered via stereotactic injections of a pTyF TGF-α 
Cre lentivirus, tumor formation was induced in mice expressing EGFRWT Ink4A/ARF-/- 
and EGFRWT Ink4A/ARF-/- PTEN-/-. Cells with those respective genotypes were then 
harvested from tumors taken from four different mice. Using cells of the same genotype 
harvested from four different mice ensures that the consistent response patterns detected 
are genotype specific as opposed to variant cell specific effects.  
 This study focuses on the differences in cell death resulting from exposure to 
gefitinib and CI-1033, two type I TKIs that have presented various challenges in their 
transition to clinical use. Clinical trials using gefitinib to treat GBM did not show an 
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increase in survival, while CI-1033 demonstrated too much toxicity in clinical trials 
treating metastatic breast cancer to be studied in GBM patients (Rixe et al., 2009; 
Vivanco et al., 2012). We sought to ascertain potential discrepancies in downstream 
signaling effects as well as the cause of cell death between the two treatments. Inhibition 
of EGFR in the absence of one or more tumor suppressor genes will allow us to glean the 
extent to which genotype plays a role in treatment outcomes and aid us in future 
prediction of which patient populations will benefit most from various therapeutic 
options. With a more comprehensive picture of the downstream effects of these drugs, we 
may begin to develop novel therapies that correct for their inadequacies, such as less 
toxic compounds that have similar effects to those induced by CI-1033, or administer 
combination therapies that target the entirety of mechanisms utilized by GBM to evade 
current treatments.  
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METHODS  
EGFR Conditional Mice & Corresponding Cell Lines 
 
 Cells expressing EGFRWT and loss of Ink4A/ARF and PTEN tumor suppressor 
genes were harvested from tumors formed in mouse models of EGFR wild-type driven 
gliomagenesis (Acquaviva et al., 2011). Conditional expression of EGFRWT was achieved 
in the mouse model according to the protocol as outlined by Zhu et al., 2009. The 2415, 
14315, and 14806 cell lines were isolated from EGFRWT/Cdkn2a-/-/PTEN-/- tumors.  
The 2000 cell line serves as a positive control and are EGFRWT/Cdkn2a-/-. 
Cell Culture 
 Cells were maintained in Dulbecco’s Modification of Eagle’s Medium (DMEM) 
including 4.5g/L glucose, L-glutamine, and sodium pyruvate, with 10% fetal bovine 
serum and 1% penicillin-streptomycin. Cells were stored at 37°C in an incubator with 5% 
CO2.  
Viability Assay 
 Cells were plated in triplicate in 6 well dishes in 10% DMEM and allowed to 
adhere for 48 hours. Following plating, the cells were serum starved in 0.1% DMEM for 
24 hours. Media was changed prior to treatment in order to eliminate serum starvation as 
a contributing factor in cell death. Cells were treated with 10 µM gefitinib (LC 
Laboratories), CI-1033 (LC Laboratories), or dimethyl sulfoxide (DMSO) vehicle as the 
control. Time points included 0 (no treatment), 4, 12, 16, and 24 hours. Cells and their 
corresponding supernatant were harvested at the specified time points of drug exposure 
and viability was determined by counting live and dead cells using trypan blue exclusion.  
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Western Blotting 
Lysate Harvest 
 Cells were plated in 10cm dishes at 1x106 cells/dish. Cells were allowed to adhere 
and then serum starved in 0.1% DMEM for 24 hours. After starvation, cells were treated 
with 10 µM Gefitinib, CI-1033, or vehicle (DMSO). Treatment time points included 0, 
0.5, 1, 2, 4, 12, 16, and 24 hours. Cells were harvested by extracting the supernatant and 
scraping the remaining adhered cells into 1 mL of phosphate buffered saline (PBS). Cells 
were pelleted and lysed using SE lysis buffer (2.5 mL SE buffer, 50 µL 1 M sodium 
orthovanadate, and 100 µL protease inhibitor). Cells were allowed to lyse on ice for 10 
minutes before spinning at 14,000 rpm at 4°C for 10 minutes. The lysates were stored at -
20°C prior to protein quantification. 
Protein Quantification (Bradford Assay) 
 In order to determine the unknown concentration of protein in each cell lysate, a 
standard curve was created based on the absorbance values of known concentrations of 
Bovine Serum Albumin (BSA) mixed with Quick Start Bradford dye (Bio-Rad).  
Table 1: Standard Curve. Listed are the concentrations of BSA and Bradford dye for 
each sample needed to formulate a standard curve. 
 
Concentration 
(µg/µL) 
0 2 4 6 8 10 
BSA (µL) 0 1 2 3 4 5 
Bradford dye 
(µL) 
1000 999 998 997 996 995 
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Absorbance values of each sample were recorded at 595 nm. After using the 
standard curve and sample absorbance values to calculate the unknown concentration of 
protein in each lysate, samples were prepared.  
Gel Electrophoresis & Transfer 
 Equal amounts of protein were loaded into Tris/Glycine sodium dodecyl sulfate-
polyacrylamide gels and run at 150 V until the desired ladder bands were detected. The 
gel proteins were then transferred to Immobilon polyvinylidene difluoride membranes 
(Millipore) in 1L of 1X Tris-Glycine at 100V for 1 hour at 4°C. Membranes were 
blocked in 6% BSA dissolved in 1X Tris Buffered Saline-Tween (TBS) for 1 hour at 
room temperature, then incubated overnight at 4°C in primary antibody diluted in 
blocking solution. After overnight incubation, primary antibody was removed from the 
membranes and they were washed four times in 1X TBS-Tween for 15 minutes per wash 
at room temperature. After washing, secondary antibody was applied to the membranes in 
blocking solution for 1 hour at room temperature. Following the incubation with 
secondary antibody, the membranes were again washed four times in 1X TBS-Tween for 
15 minutes per wash at room temperature.  
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Table 2: Antibodies. Antibodies used to detect various proteins in cell lysates. 
Secondary antibodies were purchased from Millipore. 
 
Primary 
Antibody 
Dilution 
Factor 
Secondary 
Antibody 
(1:5000) 
Manufacturer  Catalog 
Number 
p-EGFR Y-
1068 
1:1000 Rabbit Cell Signaling 
Technologies 
2234S 
EGF Receptor 
D38B1 
1:1000 Rabbit Cell Signaling 
Technologies 
4267P 
Dynamin 1:2000 Mouse BD Biosciences 610246 
Mouse 
monoclonal 
anti-β Tubulin 
clone 
1:2000 Mouse Sigma-Aldrich  T4026 
Cleaved 
Caspase 3 
(D175) 
1:1000 Rabbit  Cell Signaling 
Technologies 
9661S 
Caspase 3 1:1000 Rabbit Cell Signaling 
Technologies 
9662S 
 
 
Strip & Reprobe 
 The signals for phosphorylated proteins were detected first. Once the desired 
films were developed, stripping buffer consisting of 15.5 mL distilled water, 2.5 mL 0.5 
M Tris HCl, and 2 mL 20% sodium dodecyl sulfate (SDS) was applied to the membranes 
and allowed at incubate at 55°C with rotation for 15 minutes in a hybridization oven. 
Membranes were then washed twice for 15 minutes per wash in 1X TBS-Tween and 
placed in blocking solution for 1 hour at room temperature with agitation. The exact same 
Western blot protocol was followed probing the same membranes for the presence of 
additional proteins.  
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Statistical Analysis 
  Two-tailed Student t-tests were performed on data from the cell viability assay in 
order to ascertain statistical significance in cell death resulting from each drug treatment. 
Several comparisons were made – between untreated cells and gefitinib treated cells at 
each time point, between untreated cells and CI-1033 cells at each time point, and 
between the two treatments at each time point. P values < 0.05 were considered 
significant. 
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RESULTS 
 
Viability Assay 
 The cell lines used for this study were chosen based on the similarity of their 
genotypes to common alterations and overexpression of EGFR found in GBM. In 
addition to overexpression of wild type EGFR, cell lines 2415, 14315, and 14806 have 
loss of both the PTEN and the Ink4A/ARF tumor suppressor genes, which allow 
unregulated growth and proliferation (Vitucci et al., 2013; Zhu et al., 2009). The 
genotype of the 2000 cell line is characterized by loss of only the Ink4A/ARF tumor 
suppressor gene, making it less able to proliferate beyond control and potentially more 
susceptible to treatment in comparison to the other cell lines.  
 The EGFR WT Ink4A/ARF-/- 2000 cells were sensitive to treatments with both 
gefitinib and CI-1033. When compared to the control treated cells, there was a 
statistically significant difference in the percent cell viability in gefitinib treated cells at 
12, 16, and 24 hours (P = 0.000233, 6.0255E-08, 2.2614E-17, respectively). Cells treated 
with gefitinib at 12, 16, and 24 hours showed 12.3%, 75.5%, and 84.7% reductions in 
viability compared to control treated cells (Figure 3A). Likewise, when comparing 
control and CI-1033 treated cells there was a statistically significant difference at 4, 12, 
16, and 24 hour time points (P = 0.0362, 6.1044E-07, 1.0150E-05, 1.1224E-13 
respectively) resulting in 25%, 84.1%, and 82.8% reductions in viability at 12, 16, and 24 
hours of exposure respectively (Figure 3A). There was a statistically significant 
difference between the two drug treatments at 12, 16, and 24 hours (P = 0.000562, 
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0.01579, 0.04439, respectively) with CI-1033 treatment causing more cell death at 12 and 
16 hours, but gefitinib causing more death at 24 hours (Figure 3A).  
 In contrast to the 2000 cell line, the EGFR WT, Ink4A/ARF -/-, PTEN-/- 14806 
cells, showed much less sensitivity to gefitinib treatment than to CI-1033. There was a 
statistically significant difference between gefitinib and control treated cells at 4 and 12 
hours (P = 0.03341 and 0.01118 respectively) but the percentage of viable cells remained 
relatively high throughout the entire time course, resulting in a 15.6% reduction in cell 
viability at its greatest point (Figure 3B). In contrast, the statistically significant 
difference between control and CI-1033 treated cells at 12, 16, and 24 hours (P = 4.469E-
05, 0.002838, 0.001923, respectively) was much more apparent with 44.5%, 62.7%, and 
84.8% reductions in cell viability with CI-1033 treatment (Figure 3B). The difference 
between gefitinib and CI-1033 treated cells was statistically significant at 12, 16, and 24 
hours (P = 1.877E-05, 0.000237, 0.000194, respectively) with CI-1033 producing 50.7%, 
53.6%, and 69.2% more cell death at each of the respective times (Figure 3B). Treatment 
with CI-1033 had visibly much greater impact on cell death than gefitinib.  
 The percent cell viability of the EGFR WT, Ink4A/ARF-/-, PTEN-/- 2415 cells, 
showed a small degree of cell death in gefitinib treated cells in comparison to the control 
treatment (Figure 3C). There was a statistically significant difference between the 
gefitinib and control treatments at 4 and 24 hours (P = 0.008975 and 0.0001108) with the 
cells at the 4-hour time point showing slightly less death than the control treated (Figure 
3C). In addition, there was a statistically significant difference between the control and 
CI-1033 treated cells at 12, 16, and 24 hours (P = 0.00554, 0.03578, 0.00440, 
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respectively) with the greatest decrease in viability, 57.7%, at 24 hours (Figure 3C). 
When comparing the gefitinib and CI-1033 treated cells, the difference in the percent of 
viable cells at 12, 16, and 24 hours (P = 0.001489, 0.01118, 0.001105, respectively) was 
immediately apparent. The 2415 cells showed much more sensitivity to CI-1033 than 
gefitinib overall, corresponding with 20.7%, 22.7%, and 32.8% differences in cell death 
at 12, 16, and 24 hours.  
 The EGFR WT, Ink4A/ARF-/-, PTEN-/- 14315 cells, had a statistically 
significant difference in the percent of viable cells between the control and gefitinib 
treated populations at 12 hours (P = 0.0254) and 16 hours (P = 0.00179). There was no 
significant difference between the control and gefitinib treated cells at 24 hours (P = 
0.0520), but the percent of viable cells is indicative of cell death with the greatest, 12.5%, 
reduction in viability at 24 hours (Figure 3D). There was a significant difference in cell 
viability between control and CI-1033 cells at 4, 12, 16, and 24 hours (P = 0.0283, 
0.0077, 0.000279, 4.53E-07, respectively) with 23.9%, 78.7%, and 96.3% reductions in 
cell viability at 12, 16, and 24 hours. Furthermore, when comparing gefitinib and CI-
1033 treated cells at each time point, there was a statistically significant difference 
between the two treatments at 12, 16, and 24 hours (P = 0.00245, 3.11E-06, 9.18E-07, 
respectively) indicating a much larger decrease in viability with treatment of CI-1033 
(Figure 3D).  
 Overall, the viability data indicate that the differences in the ability of gefitinib 
and CI-1033 to cause significant decreases in cell viability become apparent after 12 
hours of incubation with the drugs in cells with loss of both Ink4A/ARF and PTEN 
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(Figure 3B, 3C, 3D). In EGFR WT Ink4A/ARF-/- cells, sensitive to both gefitinib and 
CI-1033, widespread cell death begins to occur after 12 hours of incubation (Figure 3A).  
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Figure 3: Viability of EGFRWT Cells treated with TKIs. Viability assays of four 
independent tumor cell cultures with specified genotypes after administration of (10µM) 
gefitinib and CI-1033. Data are plotted as a function of percent viable cells at 4, 12 16, 
and 24 hour time points and normalized against cells treated with vehicle. Asterisks 
indicate statistical significance (P<0.05) between treated and untreated and bars with an 
asterisk indicate statistical significance between two treatments at a given time point. For 
each time point, N=3 and cells were plated as a single biological experiment counted in 
triplicate. (A) 2000 EGFRWT Ink4A/ARF-/- cells were sensitive to 10µM treatments of 
gefitinib and CI-1033. (B) 14806 EGFRWT Ink4A/ARF-/-, PTEN-/- cells were more 
sensitive to 10µM treatments of CI-1033 than gefitinib. (C) 2415 EGFRWT Ink4A/ARF-/, 
PTEN-/- cells were more sensitive to 10µM treatments of CI-1033 than gefitinib. (D) 
14315 EGFRWT Ink4A/ARF-/-, PTEN-/- cells were more sensitive to 10µM treatments of 
CI-1033 than gefitinib. 
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Western Blot Analysis 
 In order to ascertain if gefitinib and CI-1033 inhibited EGFR equally, western 
blot analysis was performed on total cell lysates to determine the level of phosphorylated 
EGFR (p-EGFR) using autophosphorylation site tyrosine 1068 as a surrogate for EGFR 
tyrosine kinase activity. The same samples were probed to detect the total amount of 
EGFR in order to ensure that the level of phosphorylation was altered due to drug 
treatments and not due to the absence of the receptor itself.  
In the Ink4A/ARF deficient 2000 cells, the p-EGFR signal was extremely 
diminished at 0.5 hours post drug treatment and the entirety of the signal had disappeared 
at 1 hour with both gefitinib and CI-1033 treatment (Figure 4). In contrast, p-EGFR was 
detected in untreated and control (DMSO) treated cells. A faint p-EGFR signal returned 
briefly at 16 hours in gefitinib treated cells. However, in CI-1033 treated cells, once the 
p-EGFR signal disappeared at 1 hour, it did not return (Figure 4).  
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Figure 4: Western Blot Analysis of EGFR WT, Ink4A/ARF-/-, pTyF TGFα cre cells 
(2000). Total cell lysates from Ink4A/ARF deficient mouse model GBM cell cultures 
analyzed for the presence of P-EGFR Y1068 and total EGFR with Dynamin and β-
Tubulin serving as loading controls. Phosphorylation of EGFR was inhibited by 1 hour 
and did not return with the exception of an extremely faint signal in the 16-hour gefitinib 
treated cells.  
 
 Cell lines that were deficient in both Ink4A/ARF and PTEN showed effective 
inhibition of EGFR with both gefitinib and CI-1033. Although the level of 
phosphorylation was diminished at 0.5 and 1 hour, 14806 cells did not show complete 
inhibition of p-EGFR in gefitinib and CI-1033 treated cells until 2 hours of incubation 
with respective drugs (Figure 5). However, at 12 hours, a p-EGFR signal returned and 
persisted in the 16 and 24-hour lysates in gefitinib treated cells. In contrast, once p-EGFR 
was eliminated in CI-1033 treated cell, it did not return (Figure 5).   
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Figure 5: Western Blot Analysis of EGFR WT, Ink4A-/-, PTEN-/-, pTyF TGFα cre 
cells (14806). Total cell lysates from mouse model GBM cell cultures deficient in 
Ink4A/ARF and PTEN were analyzed for the presence of P-EGFR Y1068, total EGFR, 
and β-Tubulin serving as a loading control. Phosphorylation of EGFR was inhibited by 2 
hours of incubation in both gefitinib and CI-1033 treated cells and started to reappear 
faintly at 12, 16, and 24 hours in gefitinib treated cells.  
 
 Although the effects of gefitinib and CI-1033 took slightly longer to manifest 
themselves in 2415 cells, which are also Ink4A/ARF and PTEN deficient, they showed a 
similar pattern to the other two cell lines with the same genotype. P-EGFR completely 
disappeared at 12 hours in both gefitinib and CI-1033 treated cells. However, p-EGFR 
reappeared in gefitinib treated cells at 24 hours with no return in the CI-1033 treated 
populations (Figure 6).  
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Figure 6: Western Blot Analysis of EGFR WT, Ink4A/ARF-/-, PTEN-/-, pTyF 
TGFα cre cells (2415). Total cell lysates from Ink4A/ARF and PTEN deficient mouse 
model GBM cell cultures analyzed for the presence of P-EGFR Y1068, total EGFR, and 
β-Tubulin serving as a loading control. Phosphorylation of EGFR was inhibited at 12 
hours for both gefitinib and CI-1033 treated cells and reappeared at 24 hours in gefitinib 
treated cells.  
 
 14315 cells, which are Ink4A/ARF and PTEN deficient as well, showed complete 
inhibition of p-EGFR at 2 hours of incubation in both gefitinib and CI-1033 treated cells 
(Figure 7). Similar to their counterparts, 14315 gefitinib treated cells showed p-EGFR 
reappearing at 16 and 24 hours. Cells treated with CI-1033 were never able to recover the 
phosphorylated EGFR once it had been completely inhibited (Figure 7).  
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Figure 7: Western Blot Analysis of EGFR WT, Ink4A/ARF-/-, PTEN-/-, pTyF 
TGFα cre cells (14315). Total cell lysates from Ink4A/ARF and PTEN deficient mouse 
model GBM cell cultures analyzed for the presence of P-EGFR Y1068, total EGFR, and 
β-Tubulin serving as a loading control. Phosphorylation of EGFR was inhibited at 2 
hours in both gefitinib and CI-1033 treated cells and reappeared faintly at 16 and 24 
hours in gefitinib treated cells.  
 
 All three EGFRWT cell lines deficient in both Ink4A/ARF and PTEN showed 
complete inhibition of EGFR relatively early in the time course with treatment of both 
TKIs and a reemergence of p-EGFR in only gefitinib treated cells (Figure 4, 5, 6, 7). This 
effect was echoed in the results of the viability assay showing that all three of these cell 
lines were more sensitive to CI-1033 than gefitinib (Figure 3B, 3C, 3D). In contrast, the 
EGFRWT cells deficient in Ink4A/ARF showed nearly equal sensitivity to both TKIs as 
reflected in both the percent of viable cells and inhibition of p-EGFR with each treatment 
(Figure 3A, 4). 
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 In order to begin to determine the effects of each drug on downstream cell 
signaling in both genotypes, the 2000 and 2415 cell lines were probed for the presence of 
cleaved caspase 3, a downstream effector caspase that is a marker of caspase-induced 
apoptosis (Guicciardi & Gores, 2009).  
 In the 2000 cells, the emergence of cleaved caspase 3 at 12 hours correlated with 
the results of the viability assay (Figure 3A) as the point in the time course of treatment 
where substantial cell death started to occur with treatment. At 12 hours, cleaved caspase 
3 exhibited a stronger signal in CI-1033 treated cells, but at 16 hours there was much 
more cleaved caspase 3 in gefitinib treated cells (Figure 8A). Although the cleaved 
caspase 3 appeared to diminish at 16 hours in CI-1033 treated cells, it returned at 24 
hours to be nearly equal to that of the gefitinib treated population. In contrast to the 2000 
cells, the 2415 cell line did not exhibit any signs of cleaved caspase 3 in either treatment 
group throughout the entirety of the time course (Figure 8B). As indicated by the viability 
data and minimal cell death in 2415 cells treated with gefitinib, the presence of cleaved 
caspase 3 was not predicted in those cells, but was anticipated to be present in cells 
treated with CI-1033 (Figure 3C). Based on consistent levels of caspase 3 in the samples 
tested, it was possible to verify that the varying levels of cleaved caspase 3 were not a 
direct result of more or less total caspase 3 in each sample (Figure 8). This stark contrast 
in cleaved caspase 3 between cells of different genotypes indicates the need to conduct 
western blot analysis for cleaved caspase 3 on the remaining cell types deficient in both 
Ink4A/ARF and PTEN as well as begin to consider testing for the presence of other 
downstream cell signaling molecules.  
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Figure 8: Comparative Western Blot Analysis of Cleaved Caspase 3 for 2000 & 2415 
cells. Total cell lysates from mouse model GBM tumor cell cultures were analyzed for 
the presence of cleaved caspase 3, total caspase 3, and β-Tubulin as a loading control. (A) 
2000 cells, deficient in Ink4A/ARF, showed a stronger signal for cleaved caspase 3 in CI-
1033 treated cells at 12 hours and a weaker signal at 16 hours in comparison to gefitinib 
treated cells. The amounts of cleaved caspase 3 appeared relatively similar for the two 
treatments at 24 hours. (B) Cleaved caspase 3 was not detected in 2415 cells, deficient in 
Ink4A/ARF and PTEN, for either gefitinib or CI-1033 treatments.  
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DISCUSSION 
 
 It has been well established that the overexpression and/or increased activation of 
EGFR is a commonality among many different cancers and is often responsible for the 
associated enhanced proliferation, angiogenesis, necrosis, treatment resistance, and other 
pathological attributes that result in poor patient prognoses (Taylor, Furnari, & Cavenee, 
2012). The common genetic abnormalities frequently encountered in GBM, including 
loss of Ink4A/ARF and PTEN tumor suppressor genes, contribute to the complexity of 
the disease and afford it the noteworthy ability to diffusely infiltrate surrounding tissue 
with a median survival of 14.6 months with current treatments (Taylor et al., 2012). The 
results of this study indicate that the impact of inhibition of EGFR on cells expressing 
EGFRWT varies with genotype and the type of inhibitor used. The insight we have gained 
into the mechanisms of EGFR inhibition has prompted the need for further investigation 
into the inhibition of cell signaling downstream of the receptor in pathways associated 
with growth, proliferation, and apoptosis.  
Cells with EGFRWT Ink4A/ARF-/- genotype showed relatively equal sensitivity to 
both gefitinib and CI-1033 (Figure 3A). In contrast, cells with EGFRWT Ink4A/ARF-/- 
PTEN-/- genotype showed a much greater sensitivity (ranging from 32.7% - 83.8% at 24 
hours) to treatment with CI-1033 compared to gefitinib and a statistically significant 
difference in the percent cell viability between gefitinib and CI-1033 treated cells at 12, 
16, and 24 hours (Figure 3B, 3C, 3D). These results indicate that CI-1033 is a more 
potent inhibitor of EGFR than gefitinib when administered at the same concentration for 
equal amounts of time. The contrasting abilities of gefitinib and CI-1033 to cause cell 
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death may be attributed to the ability of CI-1033 to irreversibly bind the adenosine 
triphosphate (ATP) binding site, affording CI-1033 the opportunity to have a more lasting 
effect on cell signaling and downstream effectors (Rixe et al., 2009).  
Our finding that CI-1033 produces a significantly greater reduction in cell 
viability than both gefitinib and control treatments indicates that complete receptor 
inhibition may be necessary to achieve the desired degree of cell death. Given that 
gefitinib inhibits EGFR to a lesser extent, the living cells remaining may retain function 
of proliferative cellular processes that could be sufficient to sustain a tumor regardless of 
therapy. Without complete receptor shut down, tumorigenic proliferation may continue, 
but at a reduced rate.  
The viability data also indicate that the loss of PTEN is crucial in determining the 
response of tumors to various treatment options and further explains its association with 
poor clinical prognoses (Krakstad & Chekenya, 2010). Without complete inhibition of 
EGFR, it is possible that downstream effector pathways such as PI3K-AKT continue to 
operate even in the presence of potent inhibitors. For this reason, the loss of PTEN in 
addition to Ink4A/ARF may explain the difference in cell viability between the two 
genotypes (Figure 3). Loss of PTEN removes the negative regulation of the PI3K-AKT 
pathway, which is crucial in the management of apoptosis, migration and cell invasion, 
and which may require much more potent inhibition of EGFR to produce cell death 
(Carrasco-García et al., 2014; Krakstad & Chekenya, 2010). Loss of PTEN at tumor 
inception has been shown to predispose tumors to resistance to EGFR inhibition and may 
confer a signaling paradigm that allows it to be more resistance to treatment with certain 
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inhibitors, gefitinib in particular (Acquaviva et al., 2011; H. J. Jun et al., 2012). 
Furthermore, loss of PTEN post tumor formation does not confer the same resistance 
indicating that signaling pathways are established at tumor onset and PTEN null tumors 
may utilize a variant signaling pathway (Acquaviva et al., 2011). Further research is 
necessary in order to determine the inhibition of downstream effectors such as AKT 
(protein kinase B), a key substrate phosphorylated downstream of PI3K, and degree of 
elimination of crosstalk among these pathways (Krakstad & Chekenya, 2010).  
Having established CI-1033 as a more effective inhibitor of EGFR compared to 
gefitinib, we sought to determine the differences between these two treatments at the 
receptor level as well as discrepancies in their effects on downstream signaling. The loss 
of PTEN at tumor formation may cause the uncoupling of PI3K-AKT signaling from 
EGFR and could play a role in resistance to gefitinib (Vitucci et al., 2013). Gefitinib, 
shown to cause G1 cell cycle arrest in PTEN null cells, may have different downstream 
targets than CI-1033, which causes widespread cell death (Acquaviva et al., 2011).  
Differences in downstream signaling may not be the only source of discrepancy 
when comparing gefitinib and CI-1033. Other variations include the level of inhibition of 
the receptor itself as well as the mechanism of cell death caused by each treatment. 
Western blot analysis indicates that both gefitinib and CI-1033 successfully inhibited 
EGFR (Figure 4, 5, 6, 7). However, genotype specific effects are evident in that p-EGFR 
disappears much more rapidly in the 2000 cells, which are EGFRWT Ink4A/ARF-/-, than 
in the three other cells lines deficient in both Ink4A/ARF and PTEN (Figure 4, 5, 6, 7). 
Although there was variation among the 14806, 14315, and 2415 cell lines with regards 
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to when the p-EGFR signal completely disappeared, it was ultimately eliminated with 
both treatments (Figure 5, 6, 7). A noteworthy and consistent difference appeared 
between gefitinib and CI-1033 in the reemergence of p-EGFR. In gefitinib treated cells of 
every genotype, a p-EGFR signal returned later in the time course. In contrast, once CI-
1033 inhibited receptor phosphorylation, the signal disappeared permanently (Figure 4, 5, 
6, 7). The return of p-EGFR in gefitinib treated cells may serve as a further indication 
that less permanent and/or incomplete inhibition of the receptor allows the persistence of 
downstream signaling and evasion of pro-apoptotic mechanisms. This data correlates 
with the results of the viability assay (Figure 3) showing that CI-1033 more effectively 
inhibits EGFR compared to gefitinib, and indicates that the more prevalent difference 
between the two drug treatments may be in their effects downstream of the receptor itself. 
In addition, only one phosphorylation site, Tyrosine 1068, was considered in the 
evaluation of EGFR inhibition. The multitude of phosphorylation sites contained within 
EGFR are connected to a variety of cell signaling pathways, which may dictate the 
difference in efficacy between gefitinib and CI-1033 (Figure 1) (“The Alain Charest Lab | 
Sackler,” n.d.). 
The differences in extent of EGFR inhibition may begin to explain the differences 
in potency between gefitinib and CI-1033, but do not address their respective effects on 
downstream cell signaling. We sought to further explain the differences in the two drug 
treatments through the presence of cleaved caspase 3, a hallmark of apoptosis (Skvortsov 
et al., 2005). Apoptosis, the counterweight to cell proliferation, exhibits different 
morphological characteristics from necrosis (pathological cell death) and includes an 
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intrinsic and extrinsic pathway (Krakstad & Chekenya, 2010). The extrinsic pathway is 
activated by ligand binding to tumor necrosis factor (TNF) receptors and may in turn 
activate the caspase cascade and intrinsic pathway (Krakstad & Chekenya, 2010). The 
intrinsic apoptotic pathway, in contrast, is activated by signals indicating DNA damage, 
oxidative stress, or growth factor deprivation (Krakstad & Chekenya, 2010).  
Western blot analysis of 2000 cells, sensitive to both gefitinib and CI-1033, 
showed two different patterns of caspase 3 activation with different treatments. In 2000 
cells treated with gefitinib, a faint cleaved caspase 3 signal appears at 12 hours followed 
by a strong and persistent signal at 16 and 24 hours (Figure 8A). In contrast, 2000 cells 
treated with CI-1033 showed a faint cleaved caspase 3 signal at 12 and 16 hours and a 
strong signal at 24 hours (Figure 8A). Given that the viability data for this cell line show 
a similar sensitivity to both treatments (Figure 3A), it is possible that the mechanism of 
cell death induced by CI-1033 occurs largely through a caspase-independent form of 
apoptosis. Furthermore, western blot analysis of 2415 cells, deficient in Ink4A/ARF and 
PTEN, showed an absence of cleaved caspase 3 in both gefitinib and CI-1033 treated 
cells for the entirety of the time course (Figure 8B). The absence of cleaved caspase 3 in 
CI-1033 treated cells further supports the notion that CI-1033 may induce apoptosis in a 
caspase independent manner because the viability data for those cells indicates that CI-
1033 produces a significant increase in cell death when compared to control and gefitinib 
treated cells (Figure 3C).  
Clinical data suggests that the ability of gefitinib to produce anti-tumor effects is 
determined by its ability to inhibit anti-apoptotic signaling and induce G0/1 cell cycle 
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arrest (Krakstad & Chekenya, 2010; Taylor et al., 2012). Studies examining the effects of 
gefitinib on human lung adenocarcinoma cells have also demonstrated apoptotic cell 
death and activation of caspase 3 and caspase 8 (Chang et al., 2004). Conversely, the cell 
death induced by treatment with CI-1033 has not been proven to occur through caspase 
mediated apoptotic mechanisms (Skvortsov et al., 2005). In a study of colorectal cancers 
overexpressing EGFR, cells treated with CI-1033 that died of apoptosis showed weak 
activation of caspase 3 and an increase in expression of several proteins involved in 
mechanisms of caspase independent cell death (Skvortsov et al., 2005). Colorectal cancer 
cells that died of apoptosis exhibited an increase in apoptosis inducing factor (AIF), a 
protein that is translocated into the nucleus causing chromatin condensation and DNA 
fragmentation, after 24 hours of exposure to CI-1033 (Skvortsov et al., 2005). Further 
treatment of these cells with a caspase inhibitor and CI-1033 resulted in no reduction of 
apoptosis in the cells that were sensitive to treatment (Skvortsov et al., 2005). Although 
further examination of caspase independent markers of apoptosis is necessary, our results 
indicate that treatment with both gefitinib and CI-1033 may induce varying degrees of 
apoptosis potentially occurring through different mechanisms.  
While gefitinib presents with adequate safety data but limited efficacy, CI-1033 
has demonstrated that its potency results in clinical toxicity (Rixe et al., 2009). This is 
reflected in the results of a phase II clinical trial testing the safety and efficacy of CI-1033 
in patients with metastatic breast cancer overexpressing at least one ErbB RTK (Rixe et 
al., 2009). The results of treating breast cancer patients with CI-1033 indicated significant 
increases in adverse events resulting from treatment related toxicity, but did not produce 
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clinically significant results in increasing 1 year progression free survival in patients 
(Rixe et al., 2009). 
An obstacle in the use of gefitinib and CI-1033 as monotherapies to inhibit tumor 
cells expressing EGFRWT is the co-activation of RTKs in resistant GBM cell lines 
(Chakravarti, Loeffler, & Dyson, 2002). Inhibition of EGFR has been demonstrated to 
induce an increase in c-MET, allowing continued activation of the MAPK and PI3K 
pathways (Hyun Jung Jun et al., 2014; Organ & Tsao, 2011). MET-positive cells have 
also been demonstrated to activate small populations of glioblastoma stem cells (GSC) 
which are resistant to radiation and chemotherapy, thereby aiding in tumor progression 
(Hyun Jung Jun et al., 2014). By co-targeting more than one RTK it may be possible to 
reduce therapeutic resistance by inhibiting downstream PI3K signaling and reducing c-
MET driven increases in GSCs (Chakravarti et al., 2002; Hyun Jung Jun et al., 2014).  
The results of this study have effectively confirmed that CI-1033 is a more 
effective inhibitor of cells overexpressing EGFRWT than gefitinib. Furthermore, we have 
shown that p-EGFR can return in gefitinib treated cells, which may be a contributing 
factor in its comparatively lower potency. In our examination of the presence of cleaved 
caspase 3, a downstream marker of apoptosis, it became evident that the predominant 
mechanism of apoptosis induced by CI-1033 is most likely caspase independent. Future 
western blot analysis of downstream effectors in the PI3K and MAPK pathways as well 
as for AIF and other markers of caspase independent apoptosis are necessary to shed 
more light on the differences between the two inhibitors.  
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Our limited understanding of the mechanisms employed by small molecule RTKs, 
gefitinib and CI-1033 in particular, leaves a great deal of opportunity for further research. 
Discrepancies among drug efficacy studies may stem from inadequate methods of 
biomarker determination, co-activation of multiple RTKs that allow selective persistence 
of some downstream cell signaling pathways, and possible antagonistic effects of TKIs 
on the current standard of care regimen (Krakstad & Chekenya, 2010). Current phase I/II 
clinical trials that combine gefitinib with other types of inhibitors have produced 
preliminary data that suggest the potential for minor increases in progression free survival 
of GBM patients (Krakstad & Chekenya, 2010). The knowledge gained from this study 
has begun to demonstrate the complexity associated with molecularly targeted therapies 
in the treatment of GBM as well as the role of genotype in treatment resistance and 
therapeutic response.   
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